Skip to main content
ALXO logo

ALXO · Alx Oncology Holdings Inc · Webcasts, Transcripts & Audio

Track ALXO — free
$1.02 +0.05 (+5.14%) At close · Nov 19 Play latest call Q1 2026 earnings call transcript
Market Cap
$131.86M
Shares
129.27M
Volume · Nov 19 2.95M Avg daily vol (3M) 1.17M

Alx Oncology Holdings Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Alx Oncology Holdings Inc (ALXO), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-12-01
Alx Oncology Holdings Inc (ALXO) December 1, 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-18
Alx Oncology Holdings Inc (ALXO) November 18, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-17
Alx Oncology Holdings Inc (ALXO) November 17, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-14
Alx Oncology Holdings Inc (ALXO) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-09
Alx Oncology Holdings Inc (ALXO) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Alx Oncology Holdings Inc (ALXO) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-08
Alx Oncology Holdings Inc (ALXO) Q1 2026 Earnings Call Transcript
Confident tone EVO + zanidatumab HER2-positive breast cancer data (ESMO) CD47 biomarker predictive value ALX 2004 EGFR-targeted ADC program
Diluted EPS
$-0.17
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-27
Alx Oncology Holdings Inc (ALXO) Q4 2025 Earnings Call Transcript
Confident tone CD47 biomarker validation across HER2-positive tumors Phase II ASPEN-09 breast cancer trial ALX 2004 EGFR ADC dose escalation
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-07
Alx Oncology Holdings Inc (ALXO) Q3 2025 Earnings Call Transcript
Confident tone Avorpicept development strategy / targeted IO positioning ASPEN-06 / CD47 biomarker data in gastric cancer Breast cancer phase 2 program
Diluted EPS
$-0.41
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Alx Oncology Holdings Inc (ALXO) Q2 2025 Earnings Call Transcript
Confident tone CD47 as predictive biomarker for evorpacept ASPEN-06 trial data and response rates Breast cancer program redesign
Diluted EPS
$-0.49
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Alx Oncology Holdings Inc (ALXO) Q1 2025 Earnings Call
Diluted EPS
$-0.58
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-06
Alx Oncology Holdings Inc (ALXO) Q4 2024 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-12
Alx Oncology Holdings Inc (ALXO) Q3 2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–13 of 13 webcasts
Key facts CIK 1810182 CUSIP 00166B105 13F (30d) 123 filings 108 filers Visit website Investor relations